Copyright
©The Author(s) 2021.
World J Clin Cases. Sep 26, 2021; 9(27): 8220-8225
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8220
Published online Sep 26, 2021. doi: 10.12998/wjcc.v9.i27.8220
Figure 3 Responses of lung and brain lesions to osimertinib + bevacizumab regimen.
A: At docetaxel + bevacizumab failure, before osimertinib treatment; B: 2 mo after treatment initiation, both lung and brain lesions were stable; C: 3 mo after treatment, both lesions remained stable. RAH: Right/anterior/head; RPF: Right/posterior/feet; RP: Right/posterior; LA: Left/anterior; RHA: Right/head/anterior; LFP: Left/feet/posterior.
- Citation: Zhang Y, Shen JQ, Shao L, Chen Y, Lei L, Wang JL. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report. World J Clin Cases 2021; 9(27): 8220-8225
- URL: https://www.wjgnet.com/2307-8960/full/v9/i27/8220.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i27.8220